Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...
Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ...
Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug
Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...
Merck enters obesity drug race in pact with Chinese pharma Hansoh
Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on ...
FierceBiotech4d
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
Seeking Alpha on MSN4d
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after ...
BioSpace4d
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...
Daily3d
Merck, Hansoh Pharma ink pact for oral small molecule GLP-1 receptor agonist
Rahway: Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, ...
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.
FiercePharma2d
Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...